Why cough trial endpoints may be failing promising drugs As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task. Written byAndrea Corona

Why cough trial endpoints may be failing promising drugs As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task. Written byAndrea Corona Chronic cough affects an estimated five to ten percent of adults in the US, and for years there has been no FDA-approved treatment for the condition. Despite billions invested in drug development, promising candidates have stumbled at the regulatory finish line — and some researchers argue that how trials measure cough may be as much a factor as the drugs themselves. https://www.drugdiscoverynews.com/why-cough-trial-endpoints-may-be-failing-promising-drugs-17269